Saline + Fentanyl + Dexmedetomidine + Dexmedetomidine
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedAbout Saline + Fentanyl + Dexmedetomidine + Dexmedetomidine
Saline + Fentanyl + Dexmedetomidine + Dexmedetomidine is a approved stage product being developed by Pfizer for Otitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00654329. Target conditions include Otitis.
What happened to similar drugs?
1 of 11 similar drugs in Otitis were approved
Approved (1) Terminated (2) Active (8)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00654329 | Approved | Completed |
Competing Products
15 competing products in Otitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1% + piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1% + piperacillin 2% + tazobactam 0.25% + piperacillin 4% + tazobactam 0.5% + piperacillin 8% + tazobactam 1.0% | Yuhan | Phase 1/2 | 24 |
| ofloxacin otic solution 0.3% | Daiichi Sankyo | Phase 3 | 40 |
| levofloxacin | Johnson & Johnson | Phase 3 | 40 |
| levofloxacin; amoxicillin/clavulanate | Johnson & Johnson | Phase 3 | 40 |
| V114 | Merck | Phase 3 | 40 |
| Montelukast + Placebo | Merck | Approved | 43 |
| 7-valent pneumococcal-CRM197 conjugate vaccine + 7-valent pneumococcal-OMPC conjugate vaccine | Merck | Phase 3 | 40 |
| Prevenar | Pfizer | Pre-clinical | 26 |
| Zmax | Pfizer | Phase 3 | 40 |
| Observational | Pfizer | Pre-clinical | 26 |
| amoxicillin/clavulanate postassium (Augmentin ES-600) + azithromycin SR | Pfizer | Phase 3 | 40 |
| 60 mg/kg azithromycin ER + 30 mg/kg azithromycin IR | Pfizer | Phase 2 | 35 |
| Telithromycin (HMR3647) | Sanofi | Phase 3 | 40 |
| telithromycin (HMR3647) | Sanofi | Phase 3 | 32 |
| Telithromycin + Azithromycin | Sanofi | Phase 3 | 32 |